哮喘
医学
大流行
2019年冠状病毒病(COVID-19)
疾病
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
冠状病毒
重症监护医学
儿科
免疫学
传染病(医学专业)
内科学
标识
DOI:10.1097/aci.0000000000000809
摘要
The interplay of asthma and coronavirus disease 2019 (COVID-19) in children is yet unknown. The purpose of this review is to determine the interplay of asthma and asthma therapeutics and COVID-19.There is no evidence to date that asthma is a risk factor for more severe COVID-19 outcomes, especially in children. There is actually some basis to suggest that children with atopic asthma may be at reduced risk of asthma exacerbations during COVID-19. The impact of asthma therapeutics on COVID-19 outcomes is unclear, but guidance is relatively uniform in recommending that those with asthma remain on current asthma medications. A focus on social determinants of health may be increasingly important during the pandemic and beyond.Asthma in children appears to be more friend, than foe, during COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI